<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR88503-0058 </DOCNO><DOCID>fr.5-03-88.f2.A1057</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="41">[Docket No. 88M-0094]</ITAG><ITAG tagnum="56">Serono Laboratories, Inc.; Premarket Approval of Fibrel<T4>#</T4> (Gelatin Matrix Implant)</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingits approval of the application by Serono Laboratories, Inc., Randolph,MA, for premarket approval, under the Medical Device Amendments of 1976,of Fibrel<T4>#</T4> (gelatin matrix implant). After reviewing the recommendationof the General and Plastic Surgery Devices Panel, FDA's Center for Devicesand Radiological Health (CDRH) notified the applicant by letter of February26, 1988, of the approval of the application.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Petitions for administrative review by June 2, 1988.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Nirmal K. Mishra, Center for Devicesand Radiological Health (HFZ-410), Food and Drug Administration, 8757 GeorgiaAve., Silver Spring, MD 20910, 301-427-7156.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>On April 15, 1986, Serono Laboratories,Inc., Randolph, MA 02368, submitted to CDRH an application for premarketapproval for Fibrel<T4>#</T4> (gelatin matrix implant). The device is composed of absorbablegelatin powder (denatured collagen types I and III) and epsilon aminocaproicacid in a lyophilized form. The device is indicated for use in the correctionof depressed cutaneous scars which are distendable by manual stretchingof the scar borders. The device is reconstituted with equal amounts ofthe patient's plasma and 0.9 percent Sodium Chloride for Injection, USP.On May 29, 1987, the General and Plastic Surgery Devices Panel, an FDAadvisory committee, reviewed and recommended approval of the application.On February 26, 1988, CDRH approved the application by a letter to theapplicant from the Director of the Office of Device Evaluation, CDRH.A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document.A copy of all approved labeling is available for public inspection at CDRH_contactNirmal K. Mishra (HFZ-410), address above.<ITAG tagnum="84">Opportunity for Administrative Review</ITAG>Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) of the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b)(21 CFR 10.33(b)). A petitioner shall identify the form of review requested(hearing or independent advisory committee) and shall submit with the petitionsupporting data and information showing that there is a genuine and substantialissue of material fact for resolution through administrative review. Afterreviewing the petition, FDA will decide whether to grant or deny the petitionand will publish a notice of its decison in the <T4>Federal Register</T4>. If FDA grants the petition, the notice willstate the issue to be reviewed, the form of the review to be used, thepersons who may participate in the review, the time and place where thereview will occur, and other details. Petitioners may, at any time on or before June 2, 1988, file with the DocketsManagement Branch (address above) two copies of each petition and supportingdata and information, identified with the name of the device and the docketnumber found in brackets in the heading of this document. Received petitionsmay be seen in the office above between 9 a.m. and 4 p.m., Monday throughFriday.This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs,515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h)) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21">Dated: April 25, 1988.</ITAG><ITAG tagnum="6">John C. Villforth,</ITAG><ITAG tagnum="4">Director, Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 88-9767 Filed 5-2-88; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>